Colorectal cancer: Ageing, myeloid-derived suppressor cells, and treatment: Report of two cases
Journal Title: Journal of Cancer Research & Therapy - Year 2018, Vol 6, Issue 4
Abstract
Background: Colorectal cancer (CRC) is the third cause of cancer in the world and age is a risk factor for this disease. Treatments such as surgical resection and adjuvant chemotherapy have increased the mean survival and the recurrence-free survival. However, the decrease in the frequency and function of effector T cells in addition to the increase in the frequency of myeloid-derived suppressor cells that have been reported in older individuals could contribute to the impaired efficacy in immunity against cancer. We aimed to evaluate if in old patients with CRC, the pre-treatment immunological status was correlated with patients’ outcome. Methods: Patients with CRC (n = 2) were submitted to curative surgical resection or curative surgical resection plus capecitabine/oxaliplatine. Blood was collected for the evaluation of immunological status prior to the treatment and correlated with patients’ outcome. Results: Approximately 20 months after surgery the patients presented with recurrence-free survival. Patient 2 (66-years-old) with CRC and peritoneal metastases presented higher frequency and absolute cell number of myeloid-derived suppressor cells than patient 1 (58-years-old) with CRC. Patient 2 presented a low frequency of effector memory CD8 T cells in addition to high accumulation of effector memory re-expressing CD45RA (CD4 and CD8 T cells). Conclusion: Immunological status was correlated with the disease complexity and our results suggest that removing/reducing myeloid-derived suppressor cells helps in the control of cancer progression. Immunological status is a useful, low invasive tool to identify the disease complexity and the results can be used in the future development of personal treatment according to the immunological status of the patient.
Authors and Affiliations
Valquiria Bueno, Ana L. Mandaliti, Nora M. Forones
Carboplatin-gemcitabine in the treatment of elderly patients with non-small cell lung cancer: An outcome analysis
Introduction: To compare a novel carboplatin-gemcitabine (CG) schedule with gemcitabine (G) monochemotherapy in elderly patients with advanced NSCLC. Methods: The records of all the consecutive elderly patients referred...
Clinical and pathological response to pre-operative crizotinib in a patient with ALK-translocated NSCLC
A 65-year-old non-smoker female was diagnosed with lung adenocarcinoma clinically staged as IV M1a because of bilateral pulmonary lesions. After a differential response to chemotherapy, further analyses allowed us to re-...
Evaluation of tissue 5´-Nucleotidase as tumor marker in breast and brain tumors using receiver operating characteristic curve
The pursuit of the ideal tumor marker has generated many testes for using in the diagnosis and management of cancer. Several of which are now widely available. The objective of the current study was to evaluate 5´-NT act...
EYA1 expression and subcellular localization in neuroblastoma and its association with prognostic markers
Neuroblastoma, the most frequently occurring extracranial solid tumor of childhood, arises from neural crest-derived cells that are arrested at an early stage of differentiation in the developing sympathetic nervous syst...
Lichenoid mucocutaneous syndrome a variant of para neoplastic pemphigus (PNP) following the treatment of follicular non-Hodgkin’s lymphoma with fludarabine
Background: Paraneoplastic pemphigus (PNP) is an autoimmune mucocutaneous disease associated with cancer. Since the original description of the condition, various publications have suggested the presence of a heterogeneo...